Viking Therapeutics Statistics
Viking Therapeutics (0VQA) Stock Statistics & Valuation Metrics
Total Valuation
Viking Therapeutics has a market cap or net worth of $3.65B. The enterprise value is $3.14B.
- Market Cap
- $3.65B
- Enterprise Value
- $3.14B
Share Statistics
Viking Therapeutics has 127,522,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 127,522,190
- Owned by Insiders
- 2.71%
- Owned by Institutions
- 32.19%
Financial Efficiency
Viking Therapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -61.54%.
- Return on Equity (ROE)
- -0.56
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -61.54%
- Return on Capital Employed (ROCE)
- -0.62
- Revenue Per Employee
- 0
- Profits Per Employee
- -5.53M
- Employee Count
- 65
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Viking Therapeutics is -5.27. Viking Therapeutics’s PEG ratio is 0.07.
- PE Ratio
- -5.27
- PS Ratio
- 0.00
- PB Ratio
- 5.70
- Price to FCF
- -7.84
- Price to Operating Cash Flow
- -7.26
- PEG Ratio
- 0.07
Income Statement
In the last 12 months, Viking Therapeutics had revenue of 0 and earned -359.64M in profits. Earnings per share was -3.19.
- Revenue
- 0
- Gross Profit
- -431.00K
- Operating Income
- -393.34M
- Pretax Income
- -359.64M
- Net Income
- -359.64M
- EBITDA
- -359.15M
- Earnings Per Share (EPS)
- -3.19
Cash Flow
In the last 12 months, operating cash flow was -462.63M and capital expenditures 0, giving a free cash flow of -462.63M billion.
- Operating Cash Flow
- -462.63M
- Free Cash Flow
- -462.63M
- Free Cash Flow per Share
- -3.92
Dividends & Yields
Viking Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -12.76%
- Earnings Yield
- -18.68%
Stock Price Statistics
- Beta
- 0.75
- 52-Week Price Change
- -27.83%
- 50-Day Moving Average
- 29.78
- 200-Day Moving Average
- 32.27
- Relative Strength Index (RSI)
- 53.44
- Average Volume (3m)
- 25.97K
Important Dates
Viking Therapeutics upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Viking Therapeutics as a current ratio of 9.33, with Debt / Equity ratio of 0.02%
- Current Ratio
- 9.33
- Quick Ratio
- 9.33
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.46
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Viking Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Viking Therapeutics EV to EBITDA ratio is -5.11, with an EV/FCF ratio of -6.93.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.11
- EV to Free Cash Flow
- -6.93
- EV to Operating Cash Flow
- -6.93
Balance Sheet
Viking Therapeutics has $959.81M in cash and marketable securities with $254.69M in debt, giving a net cash position of $705.12M billion.
- Cash & Marketable Securities
- $959.81M
- Total Debt
- $254.69M
- Net Cash
- $705.12M
- Net Cash Per Share
- $5.53
- Tangible Book Value Per Share
- $4.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Viking Therapeutics is $95.06, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $95.06
- Price Target Upside
- 230.42% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -155.21%
Scores
- Smart Score
- 2
- AI Score
- ―
